An early drug discovery approach focusing on gene families can benefit from strategies that exploit common signaling mechanisms to more effectively identify and characterize novel chemical lead structures. Multiplexing, defined as the screening of multiple targets within the same experiment, is an example of this strategy. Here, the authors describe a technique that allows multiplexing of a common assay type used to study G-protein-coupled receptors: changes in intracellular Ca 2+ levels as measured by Molecular Device's fluorometric imaging plate reader (FLIPR ® ). The multiplexed FLIPR assays showed the expected pharmacological properties of single assays, with good reproducibility and Z′ factors. The authors used them to screen large compound libraries in 2 multiplexed assay designs. The 1st used a single-cell line expressing 2 different receptors and the 2nd a mixture of 2 cell lines of the same type each expressing distinct receptors. Screening using these multiplexed assays produced significant savings in reagents, time, and human resources and allowed the authors to quickly identify specific and selective hits. (Journal of Biomolecular Screening 2005:780-787) 
INTRODUCTION
T HE STUDY OF GENE FAMILIES has significantly increased the efficiency of key processes in early drug discovery. For example, it has allowed the easier identification of family members as potential novel therapeutic targets, 1,2 facilitated the development of assay platforms amenable to high-throughput screening (HTS), 1, 3, 4 simplified the development of selectivity panels for compound profiling, and aided in the construction of targeted chemical libraries. [5] [6] [7] There is a current and growing need for technology and process developments that exploit the gene family approach to increase the efficiency of HTS and enable the construction of selectivity panels. As part of a coordinated G-protein-coupled receptor (GPCR) gene family lead discovery program, we applied the general strategies of multiplexing and automation to increase HTS productivity in the context of a widely used GPCR assay platform: intracellular Ca 2+ measurement using the fluorometric imaging plate reader (FLIPR ® ).
Members of the GPCR family of receptors are of considerable biological and pathological interest and are therefore an important source of drug discovery targets. They are also the largest family of cell surface receptors, with approximately 800 members in the human genome. 1, 8 GPCRs are regulated by a wide spectrum of diverse stimuli (e.g., small molecules, small peptides, proteins, ions, neurotransmitters, amino acids, hormones, growth factors, light, odorants) and are key controllers of diverse physiological processes in both health and disease. Approximately 40% of currently marketed drugs mediate their actions through GPCRs. 9 Although these receptors transduce a large number of responses, they share a set of similar signaling pathways that have allowed the development of common assay platforms to test the action of chemical compounds. 4 The introduction of cell-permeable Ca 2+ -sensing fluorescent dyes and plate readers such as the FLIPR allows the rapid and kinetic determination of the rise in cytosolic Ca 2+ levels triggered by GPCR activation. 10 This has become one of the primary assays for measuring GPCR function.
To meet the increasing demands of compound testing created by combinatorial chemistry, technology investments in screening are focused on 3 major areas: miniaturization, automation, and multiplexing. Miniaturization attempts to increase the density of data points per plate of a particular assay format, whereas automation provides equipment to perform these assays with fewer human resources and higher reproducibility. Both of these approaches are applicable to any target class. Multiplexing, defined as the screening of multiple targets in the same experiment, is well suited to a gene family approach because it can exploit the common signaling pathways of related targets. To date, multiplexed assays have been achieved using multiple readouts, 11, 12 encoded particles, 13 or spatial localization of assays in an array format. 14, 15 Multiplexing allows for the parallel processing of multiple targets and promises to increase efficiencies, reduce costs, and improve the quality and content of screening data. In addition, it can also simplify the construction and execution of target selectivity panels. Although the use of multiplexing in hit discovery has been previously reported for kinases, nuclear receptors, and GPCRs, 11, [16] [17] [18] there are few examples of multiplexed assay systems used for large-scale HTS and none using Ca 2+ flux assays for GPCRs. Therefore, the benefits and liabilities of multiplexed Ca 2+ flux assays to large-scale screening are unknown.
Intracellular Ca 2+ measurement using the FLIPR is a common component of GPCR assay platforms because of its general applicability and high throughput. The assay is also amenable to automation and miniaturization, as fully automated stations and the use of 1536-well plates have been described. 18, 19 We took advantage of the short temporal nature of the Ca 2+ signal to sequentially analyze 2 GPCRs within the same experiment in 2 multiplexed formats. Because tissue culture for HTS is labor intensive and reproducibility is essential, in 1 case we also used a robotic instrument, the Automation Partnership's SelecT, to grow, subculture, and plate cells for testing.
MATERIALS AND METHODS

Cell lines and growth media
PEER cells that endogenously expressed chemokine receptors R1 and R2 were obtained from the Fujisaki Cell Center and cultured in RPMI 1640 containing 10% FBS, 2 mM L-glutamine, 25 mM HEPES, and 55 µM 2-mercaptoethanol. HEK293 cells were obtained from ATCC and cultured in DMEM containing 10% FBS, 2 mM L-glutamine, 25 mM HEPES, 1 mM nonessential amino acids, and 1 mM sodium pyruvate. HEK293 cells that exogenously expressed aminergic receptor R3 or chemokine receptor R4 required the addition of 400 µg/mL G418 or 100 µg/mL zeocin, 3 µg/mL blasticidin, and 2 µg/mL puromycin, respectively. All recombinant cell lines were constructed by using lipofectamine transfection (Invitrogen, Carlsbad, CA), followed by selection of stable clones. All cell culture reagents were purchased from Sigma (St. Louis, MO).
Tissue culture automation
The routine culturing, expansion, and plating of all HEK293 cells into 384-well plates was performed by a SelecT automated cell culture system (The Automation Partnership). Dissociation of cells from T-175 flasks was achieved by adding 0.25% trypsin at 4°C followed by incubation at 37°C for 10 min. The SelecT counted live cells by trypan blue exclusion using a Cedex cell counter. For expansion, 35 mL of fresh media at 4°C was combined with 3 × 10 6 live cells in new flasks and incubated in a 37°C/5% CO 2 dry incubator. R3-and R4-expressing cells were kept separate during culturing due to their different selection conditions. For plating into 384-well plates, the SelecT mixed the cell types using media without selection at a defined ratio and then used an internal Multidrop (Titertek) to add 50 µL of the cell suspension per well. After cell addition, the plates were moved to a Forma 37°C/5% CO 2 humidified incubator. Prior to the assay, the cells were cultivated for 48 h in the plates. The SelecT multiplex plating script can be obtained by contacting the authors.
Multiplexed FLIPR assay for a suspension cell line containing 2 receptors
PEER cells were grown in spinner flasks to a density of 6 × 10 5 cells/mL and centrifuged, and the supernatant was decanted. They were then loaded with the Ca 2+ sensing dye Fluo-4 by the following procedure. Fluo-4AM dye-loading solution was prepared by dissolving 1 mg Fluo-4AM in 880 µL DMSO plus 880 µL 20% (v/v) Pluronic acid. Of this solution, 44 µL was added to 15 mL of wash buffer (Hank's Balanced Salt Solution plus 25 mM HEPES and 2.5 mM probenecid) to make the final Fluo-4AM dye-loading solution. The cells were resuspended in the loading solution at a concentration of 1 × 10 7 cells/mL and incubated in a flask for 40 to 60 min in a 37°C 5% CO 2 , humidified incubator. Loaded cells were washed 2 times using warm wash buffer and resuspended at 2 to 2.5 × 10 6 cells/mL in the same buffer. For the assay, 40 µL of the cell suspension was added to each well of a clear bottom, blacksided, 384-well plate, and 2 to 5 µL of compound solution was added to each well using an Apricot Designs Personal Pipettor. Using the FLIPR's pipette head, 2 to 5 µL per well of chemokine ligand L1 was added immediately before the plates were read. The plates were then incubated 1 to 3 h at room temperature before the addition of 12 µL per well of chemokine ligand L2 by the FLIPR. All reagents were purchased from VWR or Sigma.
Multiplexed FLIPR assay for adherent cells containing different receptors
All buffers and plating parameters were the same as described in the suspension cell protocol. HEK293 cells cultured in 384-well plates were washed with 50 µL wash buffer and incubated with 15 µL Fluo-4AM dye-loading solution for 1 h at 37°C. The loaded cells were washed with 50 µL of wash buffer and then incubated at room temperature for 30 min in 30 µL of wash buffer. To start the reaction, 2 µL of compound was added to each well using an Apricot Designs Personal Pipettor. The plates were then loaded into the FLIPR, and 10 µL per well of aminergic ligand L3 was added using the FLIPR's pipette head. Once the entire stack of plates had been read, they were restacked into the FLIPR, and the reading procedure was repeated by adding 10 µL per well of chemokine ligand L4.
Data analysis
Time course data from FLIPR Ca 2+ flux assays were expressed either in terms of relative fluorescent units (RFU; Fig. 1A ) or in terms of fluorescent change over background ( Fig. 4A ). All other FLIPR data was expressed as the maximum RFU value per well minus the minimum value (MAX -MIN) after ligand addition. Dose-response curves were fitted and EC 50 /IC 50 s determined using GraphPad Prism. EC 50 /IC 50 data are presented as the mean of at least triplicate independent determinations ± standard deviation, except where noted. Z′ factors were calculated as described in Zhang and others. 20
RESULTS
Current published strategies to multiplex assays (e.g., different readouts, encoded particles, fixed arrays) cannot be easily and generally applied to Ca 2+ flux assays. To develop a simple approach to multiplex this assay type, we took advantage of a unique property of the FLIPR: the ability to temporally resolve 2 independent short-lived signals. The Ca 2+ signal from GPCR activation is transient, reaching a maximum in seconds followed by a slow decay of the signal back to baseline. Overall, the entire signal lasts an average of 4 to 5 min. We hypothesized that it would be possible to determine the activity of different receptors in the same experiment by sequentially stimulating them for short periods of time, with a delay between the 2 stimuli to allow the signaling machinery to reset. This approach would allow for the measurement of different receptors in the same assay well with concomitant savings in reagents and time. It would also enable us to quickly discard nonspecific hits that inhibit the activity of both receptors. We tested this procedure using 2 assay formats and 4 separate GPCR drug discovery targets, designated R1 through R4, with corresponding specific ligands, L1 through L4. Receptors R1, R2, and R4 were members of the chemokine receptor subfamily, and R3 was a member of the aminergic receptor subfamily. In the 1st case, R1 and R2 were endogenously expressed in the same cell type. In the 2nd, we extended the applicability of the method by using 2 recombinant cell lines of the same cell type exogenously expressing either R3 or R4.
Multiplexed FLIPR assay with 2 receptors in the same cell
We first tested this concept with a single cell type expressing 2 different chemokine receptors. Chemokines control the migration and activation of immunologically competent cells, and their respective receptors are key modulators with roles in many In separate experiments, loaded cells were treated with a maximal concentration of L1 or buffer, and the Ca 2+ response was measured with the FLIPR. After 20 min, a 2nd ligand was added to the same cells, and the Ca 2+ response was measured a 2nd time. (C) Dose response of 2 different chemokine receptor ligands in the multiplexed format. Loaded cells were treated with a concentration of L1 or L2 that was approximately pathological disease states. Activation of chemokine receptors is often coupled to transient Ca 2+ mobilization that can be detected by a FLIPR assay. In addition, there are several cell lines that express more than 1 chemokine receptor. We took advantage of an established leukemic T cell line (PEER) that expresses 2 functional chemokine receptors that we have designated R1 (ligand L1) and R2 (ligand L2). 21 There is no crossover of receptor selectivity by either ligand (L2 is not a ligand for R1 nor is L1 for R2), which allows the detection of a specific signal for each receptor-ligand pair.
We developed 2 independent Ca 2+ assays on the FLIPR for R1 and R2 that showed good signal/background ratios and Z′ factors of 0.6 and 0.7, respectively. The properties of known protein agonists for these receptors were in good agreement with previously reported values, and antibodies against R2 were able to inhibit the Ca 2+ response to L2 (data not shown). No antagonists or antibodies were available to validate the R1 assay. To test our fundamental hypothesis, we sequentially determined the activity of R2 and R1 in a single FLIPR experiment ( Fig. 1A ). Treatment of PEER cells with a maximal dose of L2 induced a transient Ca 2+ signal similar to that seen in the independent R2 assay previously described. After 60 min, a maximal dose of L1 was added, resulting in a 2nd Ca 2+ transient that was similar to the signal seen in the independent R1 assay described above. This encouraging result prompted us to explore a multiplexed Ca 2+ flux assay for these receptors.
We first evaluated cellular processes such as desensitization that could affect the success of a multiplexed assay of this type. For example, activation of the fMLP receptor in a variety of cell lines hinders the response of the C5a and CXCR1/2 receptors to their specific ligands. 22, 23 Therefore, it was essential to determine that the stimulation of R1 did not affect the response of R2. As a positive control, Figure 1B shows that the addition of a maximal dose of L1 20 min after treatment with the same dose of L1 produced a Ca 2+ response approximately 25% of the initial signal (see L1 + L1). When L2 was added 20 min after L1, the L2 response was not affected by the previous activation of R1 (compare L1 + L2 with buffer + L2). In a similar set of experiments, we found that the response of R1 was not significantly affected by the prior activation of R2 (data not shown). These experiments demonstrated that the activity of R1 and R2 were independent of each other at the times measured and that this receptor pair was amenable to multiplexing in this format.
It is critical that the pharmacological properties of receptors in a multiplexed format do not change. We measured the potency of L1 and L2 in a multiplexed format in Figure 1C . Both ligands showed a sigmoidal dose response with potencies equivalent to those in the individual assays (for L1, EC 50 in individual assay = 0.9 ± 0.6 nM, in multiplexed [n = 1] = 0.6 nM; for L2, EC 50 in individual assay = 0.4 ± 0.2 nM, in multiplexed [n = 1] = 0.5 nM). We saw no other differences between the currently known pharmacological properties of these receptors as measured in individual or multiplexed format.
We next used the R1/R2 multiplexed assay in a 384-well plate format to screen a large collection of chemical compounds. Two different protocols could have been used to screen the multiplexed assay: L1 and L2 can be sequentially added to each plate before moving on to the next plate, or L1 can be added to a set of plates, after which L2 is added to the same plate set. Although both procedures generated similar results, we chose the second protocol for the HTS because it was slightly more efficient. We examined a range of times between the first and second additions to ensure that the multiplexed signals were stable during the entire course of the experiment and found that the second addition could be between 20 min and 3 h after the first without interference (data not shown). To run the HTS, we added compounds to a set of 10 to 20 plates and then added a half-maximal concentration of L1 using the FLIPR. After measuring the response and waiting 1 to 3 h, we used the FLIPR to stimulate the second receptor with a half-maximal concentration of L2. Using this protocol, we screened approximately 611,000 compounds in 24 days with an average Z′ factor of 0.6 for R1 and 0.5 for R2 (summarized in Table 1 ). Compounds that demonstrated more than a 40% inhibition at 2 µM were scored as primary hits, and the hit rate (0.14% and 0.15%) was similar for both receptors. The multiplexed HTS identified 3 types of hits: R1 selective, R2 selective, and R1/R2 nonselective hits (16%-23% of the hits showed activity for both receptors). A plot of R1 inhibition versus R2 inhibition of a representative subset of confirmed hits shows the distribution of compound selectivity at 8 µM (Fig. 2) .
Multiplexed FLIPR assay with 2 receptors in different cells of the same type
Because it is difficult to find 2 receptors of therapeutic interest endogenously expressed in the same cell type, we next extended this approach to 2 recombinant cell lines that each exogenously expressed a single receptor. The co-culture of 2 different cell lines expressing 2 distinct receptors results in a mixture of cells that can sequentially respond to stimulation by both ligands. However, for proper multiplexing in this assay format, the individual assays must fulfill 2 conditions. First, the cell lines must have compatible tissue culture media and growth requirements, which can be easily achieved by using the same cell type (e.g., HEK293, CHO) to express the receptors. Second, because in a mixture there will be a lower percentage of signaling cells that contain each receptor, each individual FLIPR response should be large enough to provide a good signal after mixing and dilution. Therefore, only individual assays with a maximal FLIPR response of higher than approximately 10,000 RFU can be successfully used for multiplexing. To test this concept, we used FLIPR assays for 2 GPCRs that were developed in the HEK293 cell line: an aminergic receptor designated R3 with corresponding ligand L3, and a 3rd chemokine receptor designated R4 with corresponding ligand L4. Both individual Ca 2+ flux assays showed a FLIPR response of greater than 20,000 RFU, and the pharmacological properties of each individual assay were validated with a number of known agonists and antagonists (data not shown). We first established the optimal conditions for co-culture of the cells by testing different percentages of either R3-or R4-expressing cells in each well. Figure 3 shows the half-maximal response of mixtures carrying different percentages of each cell type at the time of seeding. We determined that plating a mixture of 50% of each cell line gave the optimal signal for both receptors in the assay.
We then tested both receptors in a multiplexed assay format in which sequential stimulation of R3 and R4 gave Ca 2+ signals compatible with HTS assay requirements (Fig. 4) . Figure 4A shows a time course of stimulation of the cell mixture by L4 (1st arrow) and L3 (2nd arrow) and demonstrates the independence of each signal. As shown in Figures 4B and 4C , the pharmacological response to both agonists and antagonists in the multiplexed assay format corresponded with data generated using homogenous populations of cells. For agonist L3, the EC 50 was 10.9 ± 3.7 nM alone and 10.7 ± 3.4 nM in the multiplexed format, and for agonist L4, the EC 50 was 2.0 ± 0.2 nM alone and 7.8 ± 0.7 nM multiplexed. For the R3 antagonist, the IC 50 was 6.8 ± 3.4 nM alone and 10.1 ± 3.7 nM in the multiplexed format, and for the R4 antagonist, the IC 50 was 16.3 ± 3.5 nM alone and 80.7 ± 12.0 nM multiplexed. The explanation for the slightly higher EC 50 for L4 and IC 50 for the R4 antagonist in the multiplexed format was unknown, but it was not a significant factor in the ability of the multiplexed HTS to identify hits.
Co-culturing cell lines in the volumes required for screening is a labor-intensive process that requires high reproducibility. To address these issues in the 2nd multiplexed HTS, we automated this step using a automated cell culture system, the SelecT (Automation Partnership). This system contains an anthropomorphic robot in a biosafety cabinet that has access to a 184-position T-175 flask incubator, a 310-position microplate incubator, a Cedex cell counter, and a 384-well Titertek Multidrop dispenser. Because it allows scheduling for unattended operation, it can provide continuous cell culture and delivery of screening plates. We transferred the HEK293 cell lines expressing R3 and R4 to the SelecT and developed a new set of protocols to allow the mixing of cells before plating. For the HTS, the SelecT cultured the cell lines separately and then added the desired amount of each cell line to a predetermined media volume before plating. The SelecT provided cells in 384well plates 3 times a week with a high degree of reproducibility and viability during the screen.
We used the R3/R4 multiplexed assay to screen approximately 1,333,000 compounds in a 384-well plate format (summarized in Table 1 ). As with the previous multiplexed HTS, we could have screened the plates sequentially or in batches by ligand. Both procedures gave similar results, so we chose to add compounds to a set of 10 to 20 plates and then measure the response to L3 in the entire Circles represent compounds that are primarily selective for R1, squares represent compounds that are primarily selective for R2, and triangles represent compounds that are approximately equipotent for both receptors.
FIG. 3. Dependence of Ca
2+ responses on percentage of 2 cell types. Two cell types, one expressing an aminergic GPCR (R3) and the other expressing a chemokine GPCR (R4), were separately cultured and plated into 384-well plates at the indicated percentages. After 48 h of co-culture, the cells were loaded with Fluo-4, and the Ca 2+ response to their respective ligands was measured on the FLIPR. plate set. The response to L4 was then determined for the same plate set in a similar manner. Because different populations of cells were being stimulated with each ligand, the 2nd addition could be done as soon as the 1st signal had decayed to background (approximately 3 min) or as long as 3 h after the first without interference. With the SelecT performing all tissue culture and providing assayready plates, we ran the complete screen in 26 days. The multiplexed HTS format performed well, displaying average Z′ factors of 0.6 for both receptors. The primary hit rate was 0.11% and 0.07% for the R3 and R4 receptors, respectively, and we scored as positive hits compounds that showed greater than 50% inhibition at 3.8 µM. Similar to the previous multiplexed HTS, we identified 3 types of hits: R3 selective, R4 selective, and R3/R4 nonselective hits.
DISCUSSION
We have successfully developed and evaluated a unique approach to multiplex Ca 2+ flux assays on the FLIPR that can be applied to HTS. The approach is straightforward, applicable to most GPCRs, and can be used in several assay designs. The sequential analysis of Ca 2+ responses has been extensively used to study desensitization and cross desensitization of GPCRs; in this article, we extend its application to the screening of large compound libraries.
We used 2 different GPCR multiplexed assays in 2 different protocols to screen a large compound library. The pharmacological properties of the multiplexed receptor assays did not differ significantly from the nonmultiplexed assays, as the potencies for both agonists and antagonists were similar in every assay analyzed. Similarly, the data quality obtained with the multiplexed assays was equivalent to the individual assays, as measured by the consistent Z′ factors of 0.5 to 0.6 in both cases. To further increase throughput, we successfully combined this multiplexing approach with automated tissue culture by using the SelecT. The application of these multiplexing and automation strategies resulted in significant savings of reagents and time and allowed us to efficiently identify selective hits for each receptor.
The simplicity of the multiplexed format is a major advantage of this approach. By leveraging the endogenous expression of 2 receptors in the same cell, we can reduce both assay development time and cell production requirements for a screen. However, it is difficult to find cell lines endogenously expressing more than 1 receptor of therapeutic interest. This issue can be solved by the coculture of the same or similar cell lines expressing different receptors. In this instance, cell production is labor intensive and reproducibility is critical, which we addressed by the use of automation. Other multiplexed assay formats could also be developed. For example, a cell line carrying an endogenous receptor could be multiplexed by transfecting in a 2nd receptor of interest, or a single cell line carrying 2 exogenously expressed receptors could be developed. However, in these cases, cross-desensitization of the signal and recovery of the cells after initial stimulation could potentially restrict its application. In contrast, when we co-culture separate and cells expressing a chemokine GPCR (R4 with ligand L4) were cultured separately and then plated into the wells of a 384well plate at a ratio of 1:1. After 48 h of incubation, the cells were loaded with Fluo-4, and the Ca 2+ response to sequential ligand addition was measured on the FLIPR. The first arrow indicates when a half-maximal dose of L4 was added, and the second arrow indicates when an half-maximal dose of L3 was added. (B) Dose response of L3 and L4 in the multiplexed format; 1:1 mixtures of cells expressing R3 or R4 were first stimulated with various concentrations of L3 to generate a dose-response curve, and then the same plate of cells was stimulated with various concentrations of L4 to generate the other dose-response curve. (C) Antagonist inhibition curve in multiplexed format; 1:1 mixtures of cells expressing R3 or R4 were treated with combinations of various concentrations of 2 common published antagonists of R3 and R4 to generate dose-response curves. After a 10-min incubation, cells were treated with a half-maximal concentration of L3, and the Ca 2+ response was measured on the FLIPR. The same plate of cells was then treated with a half-maximal concentration of L4, and data were collected a 2nd time.
cell lines that express different receptors, these 2 processes are not critical. The outcome is determined only by the ability to co-culture the cells and the size of the individual signals. We have generated proof-of-concept data that successfully demonstrate the multiplex use of 2 different cell types with 2 different nonadherent cell lines that express endogenous chemoattractant and chemokine GPCRs (data not shown). It is also possible to analyze different combinations of adherent and nonadherent cell lines carrying distinct receptors without the need for co-culture by mixing them immediately before the FLIPR experiment.
Screening multiplexed FLIPR assays provides several advantages over traditional assays, as the simultaneous analysis of several receptors can result in savings of reagents, time, and human resources. Overall, we estimate that we achieved a 40% savings in consumables and chemical compounds, a 35% savings in tissue culture resources, and a 30% savings in the time and effort to complete the screens. The SelecT required one-third of the human resources required to culture the cells by hand and significantly increased the plate-to-plate reproducibility of the assay. These findings underscore the value of multiplex and automation strategies to improve HTS efficiency.
Another key advantage of the multiplexed assay format is the rapid and efficient identification of specific and/or selective hits. False-positive hits are a problem for any type of HTS assay because compounds can affect downstream signaling steps of the receptor or have chemical properties that interfere with the detection modality. The majority of these nonspecific compounds are discarded after running a counter screen with an assay for an unrelated receptor. Through multiplexing, we can simultaneously run either screen and counter screen (for unrelated receptors) or screen and selectivity screen (for related receptors) to determine specificity or selectivity. We provide 2 examples of the 1st scenario in this article. Although both R1 and R2 belong to the chemokine GPCR subfamily, they have an overall sequence identity of only 37%. R3 and R4 belong to unrelated GPCR subfamilies and have a sequence identity of only 20%. The percentage of nonspecific hits that were identified in the screens ranged from 7% to 23%, and their early dismissal increased the efficiency of the hit discovery process.
The multiplexed approach to Ca 2+ flux assays described here offers several advantages over current assays or technologies applied to multiplex target-based assays. Successful multiple end point assays such as the dual firefly and Renilla luciferase reporter gene assay 11, 12 have the potential for use in HTS. However, these reporter gene assays have longer incubation times, contain additional steps, and require cell lysis to determine the activity of the reporter enzyme. Novel technologies for multiplexing target-based assays, such as membrane arrays for the study of GPCRs or the use of multiple biosensors in high-content screening, 24 are currently in development and may also expand the utility of multiplexing. In comparison, the multiplexed Ca 2+ flux assay described here offers several advantages. First, it is easy to apply and does not require additional equipment. The instrumentation used for the single assay is sufficient to analyze the multiplexed assay and confirm the hits. Second, we have successfully demonstrated its application to large-scale HTS. Third, it can concurrently identify specific and/or selective hits, thereby simplifying the characterization of primary hits. Fourth, it is applicable to nearly any GPCR that can produce, or be engineered to produce, a robust Ca 2+ flux upon stimulation. In addition to the 4 chemokine, 1 aminergic, and 1 chemoattractant receptor described above, we have validated the multiplex approach for an additional 4 chemokine, 1 peptidergic, and 1 purinergic receptors. The applicability of the approach to any given receptor pair can be easily estimated by determining the size of the signal of each individual receptor and by comparing the cell culture conditions of the cell lines if more than 1 is used.
There are 2 major limitations of this approach. First, only a limited number of assays can be multiplexed at once due to the method's inherent technological limitations (co-culture conditions, signal strength, the effect of desensitization and/or cell recovery processes). Second, not all GPCRs can be assayed by their ability to raise intracellular Ca 2+ , although the use of promiscuous and chimeric G-protein α subunits can be used to increase the number of GPCRs that can be assayed in this manner. 1 Multiplex screening of multiple targets in the same well is a rapidly developing area in HTS. The simple multiplexed approach described here, based on the temporal resolution of Ca 2+ flux signals with the FLIPR, adds to the available assay technologies to screen GPCRs. It produces significant savings in reagents, compounds, time, and human resources and generates more information than screening single assays. Its ability to identify specific and/or selective hits facilitates postscreen hit characterization. Finally, because short-lived signals are an integral part of different signaling pathways, multiplexing approaches based on the temporal resolution of signals have the potential to be applied to other gene families and/or assays.
